Published: Sept. 27, 2012 at 6:11 PM

CAMBRIDGE, England, Sept. 27 (UPI) -- More extensive international efforts need to be taken to prevent biotechnology being used to commit biological terrorism, a U.N. official says.

Piers Millet from the U.N. Biological Weapons Convention, speaking at the BioDesign Forum on synthetic biology being held in the Britain, warned there was no global organization with the power to ensure biotech did not fall into the hands of those who would used it for "nefarious" purposes, the BBC reported Thursday.

"If you look at the history of the last century we see a very clear trend -- every time we make a major step forward in our understanding of biology, we find a weapons application for it," he said.

He cited several major instances of biological attacks in the past few decades, as when the Japanese doomsday cult Aum Shinrikyo released anthrax spores in Tokyo in 1993.

"The traditional approach of the international community to dealing with weapons is this - they recognize a threat, develop a treaty, and then they turn that treaty into some operational form, normally by trying to control technology associated with it," Millet said.

"It has very strong models in nuclear and chemical spheres -- but not in regards to synthetic biology."

Excerpt from:
U.N. calls for biotechnology controls

RICHMOND, Va.--(BUSINESS WIRE)--

The Virginia Biotechnology Association (Virginia Bio), the premier statewide non-profit trade association for life science industries, has named its interim executive director to the full-time position of chief executive officer.

With an extensive background in the law and non-profit sectors as well as the life sciences, Jeffrey Gallagher brings leadership and policy expertise to his newly defined role, where he will be responsible for developing and executing the associations strategic plans, prioritizing the organizations areas of advocacy and serving as a voice for the organization and its over 200 member companies.

Virginia Bio is thrilled to have someone with Jeffs breadth of experience, leadership skills and deep understanding of the challenges and opportunities facing the life sciences industry, said Michael Grisham, chairman of the board at Virginia Bio. He will serve as an articulate and respected champion for our diverse member companies, particularly at a time when the life sciences throughout Virginia are emerging as an increasingly important growth sector.

Virginia Bio is on the vanguard of the rich life sciences industry throughout the Commonwealth. Not only does itserve its members andmaintain the pulse of this important business sector, but it helps to educate and provide context to many forward-looking issues related to Virginias future growth,innovationand competitiveness, says Gallagher. Ive admired this organization for many years and am now proud and pleased to serve as its new CEO. I look forward to servingour member companies,collaborating with others around the state,and working with policymakersat every levelto create jobs to Virginia and faster cures and better treatments to our citizens.

Gallagher was most recently with Lyotropic Therapeutics, Inc., based in Ashland, Va., where he served as Vice President & General Counsel. He helped establish and grow the small pharmaceutical company and was responsible for all legal matters, including regulatory compliance, personnel and intellectual property. Gallagher also has been involved with numerous non-profit organizations in various leadership roles.

One of the first priorities for Jeff as CEO is to lead the Virginia delegation at the Mid-Atlantic Bio Conference cohosted by Virginia Bio each year. Mid-Atlantic Bio, taking place this week in Bethesda, MD, brings together a critical mass of key industry stakeholders in a forum designed to improve the business climate and foster innovation. This years theme, New Alliances, New Opportunities reflects the addition of The North Carolina Biotechnology Center as a strategic partner, along with two special sessions, Best Practices for Working with the FDA and SBIR/STTR: Strategies, Program Changes and Opportunities. To view the complete program, please visit the conference website, http://www.midatlanticbio.org

About Virginia Bio

Virginia Bio is the premier statewide non-profit trade association for life science industries in Virginia. Celebrating its 20th year, Virginia Bio is an advocate for the biopharmaceutical and device industries among federal, state and local policy-makers. Virginia Bio is the official state affiliate of the Biotechnology Industry Organization (BIO). To learn more, visit http://www.vabio.org.

About Mid-Atlantic Bio

View post:
Virginia Bio Announces New Executive Leadership

WASHINGTON--(BUSINESS WIRE)--

The Biotechnology Industry Organization (BIO) announces Therapeutic Workshops on Cancer stem cell therapy, kinase drugs, and ultra rare diseases planned for the upcoming BIO Investor Forum. Hosted by BIO, the 11th annual event will take place at the Palace Hotel on October 9-10 in San Francisco, Calif.

This years Therapeutic Workshops will address some of the most exciting therapeutic advances for the biotech industry. We have worked very closely with this years esteemed Advisory Committee to identify topics that will engage investors and industry alike, said Alan Eisenberg, executive vice president, Emerging Companies & Business Developmentat BIO.

Therapeutic Workshops will feature senior-level industry executives, scientific officers and leading clinical experts that represent innovative investment opportunities in the biotech industry.

Therapeutic Workshops include:

The BIO Investor Forum features public and venture-stage company presentations, expert-led, business roundtables, one-on-one investor meetings and networking opportunities.

To learn more about the BIO Investor Forum, including registration and program information, please visit here. Advance media registration is available here. Registration is complimentary for credentialed members of the media and qualified investors.

BIO is pleased to recognize the leadership provided by the BIO Investor Forum Conference sponsors including Supporting Bank Stifel, Nicolaus & Company. BIO Double Helix and Helix Sponsors include Abbott Biotech Ventures, Amgen Ventures, Baxter Ventures, J&J Development Corporation, MedImmune Ventures, GlaxoSmithKline, Merck and Pfizer.

About BIO

BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the worlds largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIO produces BIOtechNOW, an online portal and monthly newsletter chronicling innovations transforming our world. Subscribe to BIOtechNOW.

Follow this link:
BIO Announces Therapeutic Workshops for 11th Annual BIO Investor Forum

WASHINGTON--(BUSINESS WIRE)--

The Biotechnology Industry Organization (BIO) applauds Sens. Robert Menendez (D-NJ) and Olympia Snowe (R-ME) and Reps. Jim Gerlach (R-PA) and Richard Neal (D-MA) for introducing the High Technology Small Business Research Incentives Act (H.R. 6559/S.3595).

Biotech companies are working every day to solve the greatest challenges facing our society whether its finding a cure for cancer, protecting against bio-terror threats, or creating renewable energy and renewable chemicals.

Biotech R&D is a particularly high-risk undertaking because of the substantial start-up costs, lengthy experimentation period, and possibility that the technology will not prove viable. The legislation would make it more attractive to invest in biotech and other high tech industries.

Under the proposal, biotech companies would be able to enter into joint ventures with investors, who could then utilize the losses and tax credits of an R&D project. The bill would apply to entities that devote a significant percentage of their expenses to R&D, have fewer than 250 employees, and have less than $150 million in gross assets. It is important to note that this legislation does not create any new tax incentives.

BIOs President and CEO Jim Greenwood made the following statement:

Biotechnology is a leading force for innovation in America - and innovation is key for our economic health and prosperity. Today, our small companies face significant hurdles to raise early stage capital. Every step we take to increase investment could provide important capital for groundbreaking biotech R&D projects.

Through the tax code, Congress historically has provided opportunities that encourage private investment in pre-revenue, R&D-intensive companies. The early growth of the biotech industry in the 1980s was due in part to the ability of investors to support projects aimed at finding new cures and treatments through similar joint ventures. This legislation will help spur greater private investment in biotech and other R&D intensive industries.

BIO applauds the sponsors of this bill and pledges to work with the Congress to ensure this legislation is passed.

About BIO

View post:
BIO Praises Introduction of the High Technology Small Business Research Incentives Act

Background:
As one of the best xylose utilization microorganisms, Scheffersomyces stipitis exhibits great potential for the efficient lignocellulosic biomass fermentation. Therefore, a comprehensive understanding of its unique physiological and metabolic characteristics is required to further improve its performance on cellulosic ethanol production.
Results:
A constraint-based genome-scale metabolic model for S. stipitis CBS 6054 was developed on the basis of its genomic, transcriptomic and literature information. The model iTL885 consists of 885 genes, 870 metabolites, and 1240 reactions. During the reconstruction process, 36 putative sugar transporters were reannotated and the metabolisms of 7 sugars were illuminated. Essentiality study was conducted to predict essential genes on different growth media. Key factors affecting cell growth and ethanol formation were investigated by the use of constraint-based analysis. Furthermore, the uptake systems and metabolic routes of xylose were elucidated, and the optimization strategies for the overproduction of ethanol were proposed from both genetic and environmental perspectives.
Conclusions:
Systems biology modelling has proven to be a powerful tool for targeting metabolic changes. Thus, this systematic investigation of the metabolism of S. stipitis could be used as a starting point for future experiment designs aimed at identifying the metabolic bottlenecks of this important yeast.Source:
http://www.biotechnologyforbiofuels.com/rss/

Ovizio Imaging Systems and Applikon Biotechnology jointly announce today the signing of a long term worldwide marketing and distribution agreement for an innovative device using a proprietary imaging technology in microscopy.

Applikon will market worldwide an innovative and integrated solution, developed by Ovizio, that combines 4D microscopic imaging with the Applikon bioreactor systems. This new device will offer automated on-line information on cell density, cell viability and morphologic state of the cells.

Applikon and Ovizio have a common vision of the potential of optical image analysis in bioprocessing said Erik Kakes, commercial director of Applikon Biotechnology. "We feel that using optical 4D image analysis for determination of biomass concentration and viability is only the first step in applying this revolutionary technology to the bioprocess industry", he added.

We are absolutely delighted to partner with a company having such an in-depth knowledge of the market and strong reputation within the Bioprocess industry, said Philip Mathuis, CEO of Ovizio. We believe that quantitative imaging as a new Process Analytical Technology (PAT) applied to on-line bioreactor monitoring will allow Biopharma customers to improve process knowledge, quality and productivity in their R&D, Pilot and Production environments.

The new device will be jointly presented at the next Het Instrument Amsterdam, exhibition on 26 September 2012.

About Ovizio Imaging Systems NV/SA Ovizio is a spin-off company of the Universit Libre de Bruxelles (ULB). The company designs, develops and markets 4-D quantitative imaging systems and sensors based on patented Digital Holographic Microscopy with a primary focus on the Life Science Research, Biotechnology and Bioprocessing industry..

Ovizios platform technology unifies real-time quantitative imaging with speed and a label-free, non-invasive approach. Our advanced devices generate high quality holographic images ideal for studying dynamic phenomena, breaking the barriers between the traditional speed of flow cytometry and the resolution of classical microscopy.

Ovizio is a privately held company situated in Brussels, Belgium. For more information, visit http://www.ovizio.com.

SOURCE: Applikon Biotechnology

See the original post:
Ovizio And Applikon Biotechnology Sign Long Term Marketing And Distribution Agreement

Background:
A complete saccharification of plant polymers is the critical step in the efficient production of bio-alcohols. Beta-glucosidases acting in the degradation of intermediate gluco-oligosaccharides produced by cellulases limit the yield of the final product.
Results:
In the present work, we have identified and then successfully cloned, expressed, purified and characterised 4 highly active beta-glucosidases from fibre-adherent microbial community from the cow rumen. The enzymes were most active at temperatures 45--55[degree sign]C and pH 4.0-7.0 and exhibited high affinity and activity towards synthetic substrates such as p-nitrophenyl-beta-D-glucopyranoside (pNPbetaG) and pNP-beta-cellobiose, as well as to natural cello-oligosaccharides ranging from cellobiose to cellopentaose. The apparent capability of the most active beta-glucosidase, herein named LAB25g2, was tested for its ability to improve, at low dosage (31.25 units g-1 dry biomass, using pNPbetaG as substrate), the hydrolysis of pre-treated corn stover (dry matter content of 20%; 350 g glucan kg-1 dry biomass) in combination with a beta-glucosidase-deficient commercial Trichoderma reseei cellulase cocktail (5 units g-1 dry biomass in the basis of pNPbetaG). LAB25g2 increased the final hydrolysis yield by a factor of 20% (44.5 +/- 1.7% vs. 34.5 +/- 1.5% in control conditions) after 96--120 h as compared to control reactions in its absence or in the presence of other commercial beta-glucosidase preparations. The high stability (half-life higher than 5 days at 50[degree sign]C and pH 5.2) and 2--38000 fold higher (as compared with reported beta-glucosidases) activity towards cello-oligosaccharides may account for its performance in supplementation assays.
Conclusions:
The results suggest that beta-glucosidases from yet uncultured bacteria from animal digestomes may be of a potential interest for biotechnological processes related to the effective bio-ethanol production in combination with low dosage of commercial cellulases.Source:
http://www.biotechnologyforbiofuels.com/rss/

Due to a growing world population and increasing welfare, energy demand worldwide is increasing. To meet the increasing energy demand in a sustainable way, new technologies are needed. The Plant-Microbial Fuel Cell (P-MFC) is a technology that could produce sustainable bio-electricity and help meeting the increasing energy demand. Power output of the P-MFC, however, needs to be increased to make it attractive as a renewable and sustainable energy source. To increase power output of the P-MFC internal resistances need to be reduced. With a flat-plate P-MFC design we tried to minimize internal resistances compared to the previously used tubular P-MFC design. With the flat-plate design current and power density per geometric planting area were increased (from 0.15 A/m2 to 1.6 A/m2 and from 0.22 W/m2 to and 0.44 W/m2)as were current and power output per volume (from 7.5 A/m3 to 122 A/m3 and from 1.3 W/m3 to 5.8 W/m3). Internal resistances times volume were decreased, even though internal resistances times membrane surface area were not. Since the membrane in the flat-plate design is placed vertically, membrane surface area per geometric planting area is increased, which allows for lower internal resistances times volume while not decreasing internal resistances times membrane surface area. Anode was split into three different sections on different depths of the system, allowing to calculate internal resistances on different depths. Most electricity was produced where internal resistances were lowest and where most roots were present; in the top section of the system. By measuring electricity production on different depths in the system, electricity production could be linked to root growth. This link offers opportunities for material-reduction in new designs. Concurrent reduction in material use and increase in power output brings the P-MFC a step closer to usable energy density and economic feasibility.Source:
http://www.biotechnologyforbiofuels.com/rss/

Quincy College has been awarded a $2.9 million federal grant to train students in the biotechnology industry.

U.S. Labor Secretary Hilda L. Solis announced Wednesday $500 million in grants to 54 community colleges and universities around the country for the development and expansion of training programs.

Quincy College received $2,995,441 for its biotechnology and compliance program.

The school will offer an associate of science program in biotechnology and compliance and a one-year certification program in biotechnology and compliance.

According to the colleges federal application, the program will integrate virtual laboratories into an evidence-based, blended-learning approach.

It will combine training on traditional manufacturing technology with emerging, in-demand technology.

Program partners from the biotechnology industry will provide paid internships to program students in the field.

The resulting program credentials will meet the Boston areas growing demand for specialized middle-skills technicians, as well as the areas need for jobs for displaced workers, the application reads.

The funding stems from the federal Trade Adjustment Assistance Community College and Career Training Grant Program, which was authorized in 2009.

The 2010 Health Care and Education Reconciliation Act included $2 billion over four years to fund the program.

Read the original post:
Quincy College gets $2.9M for biotechnology training

Background:
Down-regulation of the caffeic acid 3-O-methyltransferase EC 2.1.1.68 (COMT) gene in the lignin biosynthetic pathway of switchgrass (Panicum virgatum) resulted in cell walls of transgenic plants releasing more constituent sugars after pretreatment by dilute acid and treatment with glycosyl hydrolases from an added enzyme preparation and from Clostridium thermocellum. Fermentation of both wild-type and transgenic switchgrass after milder hot water pretreatment with no water washing showed that only the transgenic switchgrass inhibited C. thermocellum. Gas chromatography--mass spectrometry (GCMS)-based metabolomics were undertaken on cell wall aqueous extracts to determine the nature of the microbial inhibitors.
Results:
GCMS confirmed the increased concentration of a number of phenolic acids and aldehydes that are known inhibitors of microbial fermentation. Metabolomic analyses of the transgenic biomass additionally revealed the presence of a novel monolignol-like metabolite, identified as trans-3, 4-dimethoxy-5-hydroxycinnamyl alcohol (iso-sinapyl alcohol) in both non-pretreated, as well as hot water pretreated samples. iso-Sinapyl alcohol and its glucoside were subsequently generated by organic synthesis and the identity of natural and synthetic materials were confirmed by mass spectrometric and NMR analyses. The additional novel presence of iso-sinapic acid, iso-sinapyl aldehyde, and iso-syringin suggest the increased activity of a para-methyltransferase, concomitant with the reduced COMT activity, a strict meta-methyltransferase. Quantum chemical calculations were used to predict the most likely homodimeric lignans generated from dehydration reactions, but these products were not evident in plant samples.
Conclusions:
Down-regulation of COMT activity in switchgrass resulted in the accumulation of previously undetected metabolites resembling sinapyl alcohol and its related metabolites, but that are derived from para-methylation of 5-hydroxyconiferyl alcohol, and related precursors and products; the accumulation of which suggests altered metabolism of 5-hydroxyconiferyl alcohol in switchgrass. Given that there was no indication that iso-sinapyl alcohol was integrated in cell walls, it is considered a monolignol analog. Diversion of substrates from sinapyl alcohol to free iso-sinapyl alcohol, its glucoside, and associated upstream lignin pathway changes, including increased phenolic aldehydes and acids, are together associated with more facile cell wall deconstruction, and to the observed inhibitory effect on microbial growth. However, iso-sinapyl alcohol and iso-sinapic acid, added separately to media, were not inhibitory to C. thermocellum cultures.Source:
http://www.biotechnologyforbiofuels.com/rss/

FARMINGTON, Conn., Sept. 19, 2012 /PRNewswire-iReach/ -- Global Information Inc. is the source for global biotechnology testing and screening markets and sales forecasts, strategic supplier profiles and competitive assessments. Four newly-released reports by Venture Planning Group provide global molecular diagnostics market forecasts; strategic profiles of emerging nucleic acid testing suppliers; marketing tactics used by hematology and flow cytometry suppliers; new products in the clinical chemistry testing R&D pipeline; and more.

(Photo: http://photos.prnewswire.com/prnh/20120919/CG77606)

For more information regarding sales forecasts and strategic profiles of leading biotechnology equipment suppliers or to preview samples of the full reports, please visit the link corresponding to the market of interest:

World Clinical Chemistry Testing Market

The report presents strategic profiles of current and emerging suppliers of clinical chemistry and immunodiagnostic products, including their sales, market shares, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies.

World Molecular Diagnostics Market

This report provides a worldwide overview of the molecular diagnostics market, including estimates of facilities performing DNA sequencing and molecular diagnostic testing, as well as test volume and sales forecasts by country.

World Hematology and Flow Cytometry Markets

Competitive Assessments, global market structure, business environment, and global market size and growth forecasts for hematology and flow cytometry.

World Nucleic Acid Testing Market

See the original post:
New Market Forecasts Available for Critical Global Biotechnology Testing and Screening Markets: Molecular Diagnostics ...

67 WALL STREET, New York - September 19, 2012 - The Wall Street Transcript has just published its Biotechnology and Pharmaceuticals Report offering a timely review of the sector to serious investors and industry executives. This special feature contains expert industry commentary through in-depth interviews with public company CEOs, Equity Analysts and Money Managers. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.

Topics covered: Biotechnology and Pharmaceutical Valuations - Oncology Drug Development - Orphan Drugs - FDA Approval Process - Reimbursement Trends

Companies include: Celgene Corporation (CELG), Gilead Sciences Inc. (GILD), Regeneron Pharmaceuticals Inc. (REGN), Onyx Pharmaceuticals Inc. (ONXX), United Therapeutics Corp. (UTHR), Ariad Pharmaceuticals Inc. (ARIA), Synta Pharmaceuticals Corp. (SNTA), Rigel Pharmaceuticals, Inc. (RIGL), Isis Pharmaceuticals, Inc. (ISIS) and many others.

In the following excerpt from the Biotechnology and Pharmaceuticals Report, an experienced research analyst discusses his methods for determining equity value for investors:

TWST: You prefer U.S. biotech stocks relative to U.S. pharma stocks. Please tell us your reasons for that view.

Dr. Birchenough: If you look over the last several years, the valuations for U.S. biotech stocks have contracted substantially, where if we look at valuation relative to forward earnings, the valuations are pretty close between U.S. biotech and U.S. pharma. But with U.S. biotech, what you get that you don't get with U.S. pharma is a more sustainable growth pattern for legacy products. We don't see the patent cliffs that we see for large pharma, you see better pricing power outside the U.S. and bigger opportunities for international growth, and we think you see a greater degree of innovation, which ultimately is what drives value. And the bottom line is we think there are higher barriers to entry that are established by large U.S. biotech companies than we see with large pharma.

TWST: What are some of the most exciting new drugs or technologies coming out of your companies investors would want to be aware of?

Dr. Birchenough: I think the biggest things thematically that we're seeing from a technology perspective is continued focus on molecular diagnostics guiding molecular therapeutics in oncology, in particular. And so what we're starting to see is companies succeeding at identifying key drivers of cancer-cell growth, identifying with diagnostics what those drivers are, and targeting those patients specifically with highly effective drugs. This is an area that we think we're going to continue to see growth in and where most of the oncology studies that are starting right now are being done with molecular diagnostics and better-characterized patients and more targeted drugs targeted at these oncogenic drivers of disease.

TWST: What are some of the industry-specific metrics you use to evaluate biotech and pharma companies investors in the space should also be sure to understand and analyze?

Dr. Birchenough: I think when you look at the U.S. biotech group and you're trying to figure out where to invest, I think you want to look at the maturity of the company - whether they're preclinical, whether they're development stage, Phase I through Phase III, whether they're commercial safe. I think you want to look at how well they understand their drugs, how well characterized the drugs are in earlier-stage development because, historically, companies have not spent enough time characterizing the drugs well enough and have ended up running into toxicity problems later in development.

Original post:
U.S. Biotechnology Versus Global Pharmaceutical Stocks: a Wall Street Transcript Interview with Jim Birchenough ...

67 WALL STREET, New York - September 19, 2012 - The Wall Street Transcript has just published its Biotechnology and Pharmaceuticals Report offering a timely review of the sector to serious investors and industry executives. This special feature contains expert industry commentary through in-depth interviews with public company CEOs, Equity Analysts and Money Managers. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.

Topics covered: Biotechnology and Pharmaceutical Valuations - Oncology Drug Development - Orphan Drugs - FDA Approval Process - Reimbursement Trends

Companies include: Celgene Corporation (CELG), Gilead Sciences Inc. (GILD), Regeneron Pharmaceuticals Inc. (REGN), Onyx Pharmaceuticals Inc. (ONXX), United Therapeutics Corp. (UTHR), Ariad Pharmaceuticals Inc. (ARIA), Synta Pharmaceuticals Corp. (SNTA), Rigel Pharmaceuticals, Inc. (RIGL), Isis Pharmaceuticals, Inc. (ISIS) and many others.

In the following excerpt from the Biotechnology and Pharmaceuticals Report, an experienced research analyst discusses his methods for determining equity value for investors:

TWST: You prefer U.S. biotech stocks relative to U.S. pharma stocks. Please tell us your reasons for that view.

Dr. Birchenough: If you look over the last several years, the valuations for U.S. biotech stocks have contracted substantially, where if we look at valuation relative to forward earnings, the valuations are pretty close between U.S. biotech and U.S. pharma. But with U.S. biotech, what you get that you don't get with U.S. pharma is a more sustainable growth pattern for legacy products. We don't see the patent cliffs that we see for large pharma, you see better pricing power outside the U.S. and bigger opportunities for international growth, and we think you see a greater degree of innovation, which ultimately is what drives value. And the bottom line is we think there are higher barriers to entry that are established by large U.S. biotech companies than we see with large pharma.

TWST: What are some of the most exciting new drugs or technologies coming out of your companies investors would want to be aware of?

Dr. Birchenough: I think the biggest things thematically that we're seeing from a technology perspective is continued focus on molecular diagnostics guiding molecular therapeutics in oncology, in particular. And so what we're starting to see is companies succeeding at identifying key drivers of cancer-cell growth, identifying with diagnostics what those drivers are, and targeting those patients specifically with highly effective drugs. This is an area that we think we're going to continue to see growth in and where most of the oncology studies that are starting right now are being done with molecular diagnostics and better-characterized patients and more targeted drugs targeted at these oncogenic drivers of disease.

TWST: What are some of the industry-specific metrics you use to evaluate biotech and pharma companies investors in the space should also be sure to understand and analyze?

Dr. Birchenough: I think when you look at the U.S. biotech group and you're trying to figure out where to invest, I think you want to look at the maturity of the company - whether they're preclinical, whether they're development stage, Phase I through Phase III, whether they're commercial safe. I think you want to look at how well they understand their drugs, how well characterized the drugs are in earlier-stage development because, historically, companies have not spent enough time characterizing the drugs well enough and have ended up running into toxicity problems later in development.

Read the original post:
Biotechnology Valuation Methodology: a Wall Street Transcript Interview with Jim Birchenough, Managing Director at BMO ...

67 WALL STREET, New York - September 19, 2012 - The Wall Street Transcript has just published its Biotechnology and Pharmaceuticals Report offering a timely review of the sector to serious investors and industry executives. This special feature contains expert industry commentary through in-depth interviews with public company CEOs, Equity Analysts and Money Managers. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.

Topics covered: Biotechnology and Pharmaceutical Valuations - Oncology Drug Development - Orphan Drugs - FDA Approval Process - Reimbursement Trends

Companies include: Celgene Corporation (CELG), Gilead Sciences Inc. (GILD), Regeneron Pharmaceuticals Inc. (REGN), Onyx Pharmaceuticals Inc. (ONXX), United Therapeutics Corp. (UTHR), Ariad Pharmaceuticals Inc. (ARIA), Synta Pharmaceuticals Corp. (SNTA), Rigel Pharmaceuticals, Inc. (RIGL), Isis Pharmaceuticals, Inc. (ISIS) and many others.

In the following excerpt from the Biotechnology and Pharmaceuticals Report, an experienced research analyst discusses his methods for determining equity value for investors:

TWST: You prefer U.S. biotech stocks relative to U.S. pharma stocks. Please tell us your reasons for that view.

Dr. Birchenough: If you look over the last several years, the valuations for U.S. biotech stocks have contracted substantially, where if we look at valuation relative to forward earnings, the valuations are pretty close between U.S. biotech and U.S. pharma. But with U.S. biotech, what you get that you don't get with U.S. pharma is a more sustainable growth pattern for legacy products. We don't see the patent cliffs that we see for large pharma, you see better pricing power outside the U.S. and bigger opportunities for international growth, and we think you see a greater degree of innovation, which ultimately is what drives value. And the bottom line is we think there are higher barriers to entry that are established by large U.S. biotech companies than we see with large pharma.

TWST: What are some of the most exciting new drugs or technologies coming out of your companies investors would want to be aware of?

Dr. Birchenough: I think the biggest things thematically that we're seeing from a technology perspective is continued focus on molecular diagnostics guiding molecular therapeutics in oncology, in particular. And so what we're starting to see is companies succeeding at identifying key drivers of cancer-cell growth, identifying with diagnostics what those drivers are, and targeting those patients specifically with highly effective drugs. This is an area that we think we're going to continue to see growth in and where most of the oncology studies that are starting right now are being done with molecular diagnostics and better-characterized patients and more targeted drugs targeted at these oncogenic drivers of disease.

TWST: What are some of the industry-specific metrics you use to evaluate biotech and pharma companies investors in the space should also be sure to understand and analyze?

Dr. Birchenough: I think when you look at the U.S. biotech group and you're trying to figure out where to invest, I think you want to look at the maturity of the company - whether they're preclinical, whether they're development stage, Phase I through Phase III, whether they're commercial safe. I think you want to look at how well they understand their drugs, how well characterized the drugs are in earlier-stage development because, historically, companies have not spent enough time characterizing the drugs well enough and have ended up running into toxicity problems later in development.

Read more here:
U.S. Biotechnology Stock Valuation Methodology: a Wall Street Transcript Interview with Jim Birchenough, Managing ...

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Sep 18, 2012) - Sirona Biochem Corp. (TSX VENTURE:SBM)(SRBCF)(ZSB.F), a biotechnology company specializing in carbohydrate chemistry technology, is pleased to announce that it is has engaged Ray Matthews & Associates Inc. (RM&A) to provide corporate development and strategic advisory consulting services.

"Ray Matthews and his team have a proven track record in supporting financing efforts for several biotechnology companies," stated Dr. Howard Verrico, President & CEO of Sirona Biochem. "Ray Matthews and Associates joins Sirona Biochem at an exciting time with the company focused on partnering and commercialization. Our company will benefit from RM&A''s broad range of experience in strategic planning, corporate development, investor relations and operational consultation," Dr. Verrico added.

"In our first fund (Advantage), some of our early success was due to holdings which had novel solutions addressing blockbuster markets.Sirona Biochem has a compound in development which has the potential to achieve substantial shareholder value. I am excited to be able to add value and help attract additional talent and networks to advance this program," commented Ray Matthews.

About Sirona Biochem Corp.

Sirona Biochem is a biotechnology company developing diabetes therapeutics, cancer vaccine antigens, skin depigmenting and anti-aging agents for cosmetic use, and biological ingredients.The company utilizes a proprietary chemistry technique to improve pharmaceutical properties of carbohydrate-based molecules. For more information, visit http://www.sironabiochem.com.

About Ray Matthews & Associates Inc.

Ray Matthews & Associates Inc (RM&A) is a strategic advisory firm focusing on corporate development, M&A, strategic planning and boutique IR services to Canadian and U.S.-based companies at all stages of development.For more information on RM&A Inc, please visit http://www.raymatthews.ca.

Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise.Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem''s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem''s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations.Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.

More:
Sirona Biochem Hires Ray Matthews & Associates

MADRID, September 18, 2012 /PRNewswire/ --

6th International Meeting on Biotechnology to be held atBilbao Exhibition Centre (BEC), in Barakaldo (Bilbao), from 19 to 21 September

The figures gathered to date by the BioSpain 2012 organisation show the event will be a major success and evidence the growing importance of biotechnology in Spain.

The 6th International Meeting on Biotechnology, BioSpain 2012 (http://www.biospain2012.org)-a biennial event, is organised by ASEBIO, the Spanish Association of Biotechnology Companies, in cooperation with Society for Competitive Transformation (SPRI), an agency of the Basque government, this year. BioSpain 2012 will run from 19 to 21 September in Bilbao Exhibition Centre (BEC), in Barakaldo.

International participants account for 30% of the total and twenty-five countries are represented at the event. The main countries, in terms of both participation and exhibition space, are the UK, the US, France, Germany, Mexico, Switzerland, Sweden, Belgium and the Netherlands.

The trade fair is fully booked with 216 exhibitors. The event will attract 1,450 professional visitors and 750 companies.

Also, the space for partnering/business development meetings provides room for up to 4,500 one-on-one meetings. That figure would place BioSpain in fourth place among the world's biotech business development events (from 7th place at present).

Regina Revilla, President of ASEBIO, considers that these figures evidence the importance of biotechnology in Spain. "We are very proud of the response on the part of our companies and institutions, and of the great interest that BioSpain 2012 has aroused, considering the large number of interesting biotech events in other countries. We are confident that BioSpain 2012 will fulfil participants' business expectations and help develop the industry in Spain".

A new feature of BioSpain 2012 is the biotechnology Career Fair, which will enable students and professionals to interface with companies and academic institutions in order to explore employment and training opportunities.

BioSpain 2012 also includes an Investment Forum. A total of 32 projects have been presented and will be assessed by a panel of Spanish and international experts. Other features include breakout sessions and Biotec 2012, the scientific conference of the Spanish Society of Biotechnology (SEBIOT).

Read more here:
BioSpain 2012 is Larger in Terms of Internationalisation and the Number of Exhibitors, Meetings and Visitors

By Declan Fallon - September 18, 2012 | Tickers: BIIB, ISIS | 0 Comments

Declan is a member of The Motley Fool Blog Network -- entries represent the personal opinions of our bloggers and are not formally edited.

As bullish markets expand, monies are channelled not just into established names, but to companies which offer the potential to become the next big names. In recent weeks, the number of stocks which have seen money flows above their typical average have markedly increased. Of these movers-and-shakers, one to make the grade was ISIS Pharmaceuticals (NASDAQ: ISIS).

ISIS Pharmaceuticals researches and develops antisense drugs, used for the treatment of cardiovascular, metabolic, severe and rare diseases, including cancer. The company focuses on Antisense RNA research. Antisense RNA operates like a blocker, preventing RNA (protein cooking instructions) from building proteins that may ultimately contribute or lead to disease. The company's business is to develop Antisense RNA-based drugs to a point where they can be licensed to a partner, who then commercialize it. The company has collaboration agreements with a number of companies, including Biogen Idec (NASDAQ: BIIB), Bristol-Myers Squibb, Eli Lilly,and GlaxoSmithKline.

Buyers regain momentum

ISIS Pharmaceuticals stock price has enjoyed a solid summer of 2012 after a few years of lackluster trading. The stock's nadir was 2009 when it ran into a $19 ceiling, and headed south to spend most of last year below $10 a share. But a couple of heavy trade days in early August following earnings, and more recently in September saw a shift from net selling to net buying. Largest was 3.3 million shares traded in a single day which was also so happened to come with a push above $14.

But income heavily tied to a single client

Like many biotechnology stocks, it has a variable but typically losing streak of earnings. Analyst expectations aren't a useful guide, although biotechnology stocks are probably less sensitive to earnings releases than perhaps other pharmaceutical companies which are less research focused. The company's revenues are heavily dependent on milestone payments from its research partners, Genzyme in particular. The Genzyme payments accounted for 90% and 84% of the $42.8 million and $59.1 million in reported revenue for the three and six months ended in June 30th 2012. ISIS almost squeaked a Q2 profit at a penny loss per share, although expectations for next quarter are for a $-0.28 loss.

Genzyme is working with ISIS Pharmaceuticals to develop its lead product, KYNAMRO, for the treatment of familial hypercholesterolemia. Commercialization can begin once it obtains the required regularly approval in Europe and the United States; the former application was made in June 2011, and latter to the FDA in May 2012. Submitting these applications generated a $25 payment from Genzyme. FDA approvals can take 6 to 10 months to complete, so it will be the latter part of the year until news of this is known. Should the FDA approve the commercial release of KYNAMRO then ISIS Pharmaceuticals will receive another $25 million payment from Genzyme. However, the larger picture is that ISIS Pharmaceuticals will have a new, more substantial, source of revenue in the form of license payments, not to mention a milestone payment of up to $825 million for commercialization of the drug.

However, it has more than one string to its bow

Go here to see the original:
A Biotechnology Firm Making Its First Step Towards Profitability?

Public release date: 17-Sep-2012 [ | E-mail | Share ]

Contact: Peggy Rinard rinar001@umn.edu 612-624-0774 University of Minnesota

MINNEAPOLIS / ST. PAUL (09/17/2012) Fracking, the use of hydraulic pressure to release natural gas and oil from shale, has the potential to meet energy demands with U.S. resources and stimulate the economy. However, the practice also carries possible environmental and public health risks, most notably water contamination.

A University of Minnesota research team is addressing this challenge by developing innovative biotechnology to purify fracking wastewater. Headed by Larry Wackett, a professor in the College of Biological Sciences, the team includes Alptekin Aksan, professor in the College of Science and Engineering, and Michael Sadowsky, professor in the College of Food, Agriculture and Natural Resource Sciences.

The effort has earned a new $600,000 grant from the National Science Foundation's Partnerships for Innovation (NSF-PFI) program, which pairs academic researchers with companies to transfer academic knowledge to the private sector and produce innovative technologies that benefit the public. This is the first NSF-PFI grant awarded in Minnesota. Wackett, Aksan and Sadowksy, as well as CBS Dean Robert Elde, are co-investigators. Elde's role is to lead interaction between the researchers and the companies. If the project is successful, the team will be eligible for additional NSF funding.

The three scientists, all members of the university's BioTechnology Institute, are using naturally-occurring bacteria embedded in porous silica materials to biodegrade contaminants in fracking wastewater, a technology they originally developed to remove agricultural pesticides from soil and water. They now have the ability to customize the technology to degrade chemicals in water used for fracking. Their goal is to make the water suitable for re-use in fracking of other wells and significantly reduce the amount of water used by industry.

The team will work with Tundra Companies of White Bear Lake, Minn. on silica encapsulation technologies, and Luca Technologies of Boulder, Colo. on a related effort -- using encapsulated microbes to recover natural gas from depleted coal beds. Neither company is involved in fracking. However, they see a business opportunity in helping the U.S. meet its energy needs domestically in an environmentally responsible fashion. The university's role is to further develop a platform technology that could be used by these and other companies.

Fracking relies on forcing millions of gallons of water, sand and chemicals deep into the earth, creating fissures that allow natural gas or oil to escape and be recovered. Wastewater returns to the surface where it is treated and released into surface water, injected back into the earth, or recycled for use for fracking of other wells. Chemicals present deep below the Earth's surface, as well as chemicals used in fracking may contaminate water.

Evaporation and filtration, the current treatment methods, are expensive. Moreover, they don't eliminate chemicals, they simply reduce them to a concentrated form. Industrial scale evaporation and filtration are energy intensive, and both methods leave behind a chemical residue that presents a disposal challenge.

The research team understands public concerns about the environmental impact of fracking, as well as industry concerns about misinformation related to risks, Elde says. A leading research institution, the University of Minnesota has reached out to the business community, via its large alumni network, to work together on these issues.

Read more from the original source:
UMN scientists get federal grant for biotechnology development to purify fracking water

SANTA CRUZ -- The U.S. Department of Agriculture has filed a 10-page complaint against Santa Cruz Biotechnology alleging numerous violations of the federal animal welfare act.

The complaint, dated July 19, lists incidents stemming from inspections in 2007 through May of this year, including problems with the handling of animals, inadequate veterinary care, improper food and unqualified personnel.

The USDA's complaint details a lengthy history of problems found by inspectors at the Delaware Avenue laboratory, which the agency's Animal and Plant Health Inspection Service launched an investigation into in 2010 after two inspections that year turned up a dozen sick or injured goats.

A representative from the company could not be reached to comment Monday.

Santa Cruz Biotechnology also was cited in February 2011 for noncompliance involving blood collection rules, three repeated citations and one goat that was unable to walk. Medical records for sick animals were found to be incomplete.

More recently, federal inspectors in March found that the facility had one staff veterinarian tasked with caring for 10,000 goats, about 6,000 rabbits and an undetermined number of cattle and horses.

During that inspection, as well as follow-ups in April and May, inspectors found goats with ailments ranging from an untreated broken leg, serious skin conditions and low body weight. One goat died of untreated pneumonia during an inspection on May

The company is required to file a response to the USDA's complaint within a specified time frame, or the agency will consider failure to response to constitute an admission of all allegations contained in the complaint. An oral hearing likely will be conducted if and after the company responds.

David Sacks, a spokesman for the USDA, said the company could face a penalty of up to $10,000 per violation. Determination of fines is based on multiple factors, including how egregious the violation is, the size of the facility, the facility's prior penalty history and whether the company made a good faith effort to correct the problem.

Animal rights activist Michael Budkie, executive director of Ohio-based Stop Animal Exploitation Now, said he was happy to see the USDA taking action.

See the original post:
USDA files complaint against Santa Cruz Biotechnology, alleging history of violations

Public release date: 18-Sep-2012 [ | E-mail | Share ]

Contact: Ben Norman Sciencenewsroom@wiley.com 44-012-437-70375 Wiley

Weinheim, Germany. September 18, 2012. John Wiley & Sons, Inc., has announced the signing of a new collaboration agreement between Biotechnology Journal and the Asian Federation of Biotechnology (AFOB). From 2013 the Federation will contribute two special issues to the journal annually, while representatives from the AFOB will join the editorial board.

Since launching in 2006 Biotechnology Journal has become a truly international title. Edited by Professor Sang Yup Lee, from KAIST University in South Korea, and Professor Alois Jungbauer from BOKU University in Austria, the journal attracts international authors, a global readership and will be awarded an official Impact Factor in 2013.

As a partner journal of the AFOB, the Biotechnology Journal will work with the Federation to disseminate scientific knowledge from Asian research communities to a global audience by dedicating special issues to research and breakthroughs on topics that are relevant to all biotechnologists.

A new "AFOB Highlights" section will also be introduced to the journal as a forum for reporting Federation news, announcements, prizes and awards.

The AFOB will also contribute news and views to Wiley's BiotecVisions e-magazine, which will be circulated to all Federation members on a monthly basis.

Biotechnology Journal will continue to collaborate with the European Federation of Biotechnology section on Biochemical Engineering, placing it in a unique position to serve as a bridge between European and Asian biotechnologists.

"Wiley's mission is to bring the best of science to an international audience," said Carol Bacchus, Vice President and Publishing Director, Life Sciences, Wiley. "This AFOB collaboration is a new milestone, which will foster greater international co-operation between Asian and non-Asian scientists to enhance our knowledge in all areas and applications of biotechnology and engineering technologies."

"Working with Biotechnology Journal has always been a pleasurable and successful experience for the AFOB," said Professor Ho Nam Chang, AFOB's incoming president. "We are therefore delighted to have this official agreement, which will further promote research from Asia to an international audience."

Read this article:
Wiley signs collaboration agreement with the Asian Federation of Biotechnology